Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ELX-02 in Patients With Alport Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 22, 2019
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2019
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2019
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2018
Lead Product(s) : ELX-02
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : SGS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of ELX-02 in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2017
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : SGS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : SGS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of ELX-02 in Healthy Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2017
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : SGS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2016
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable